- Home
- LIDR vs PMCB Comparison
LIDR vs PMCB Comparison
Compare LIDR & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- PMCB
- Stock Information
- Founded
- LIDR 2013
- PMCB 1996
- Country
- LIDR United States
- PMCB United States
- Employees
- LIDR N/A
- PMCB N/A
- Industry
- LIDR Auto Parts:O.E.M.
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIDR Consumer Discretionary
- PMCB Health Care
- Exchange
- LIDR Nasdaq
- PMCB Nasdaq
- Market Cap
- LIDR 9.8M
- PMCB 11.4M
- IPO Year
- LIDR N/A
- PMCB N/A
- Fundamental
- Price
- LIDR $0.70
- PMCB $1.21
- Analyst Decision
- LIDR Hold
- PMCB
- Analyst Count
- LIDR 1
- PMCB 0
- Target Price
- LIDR N/A
- PMCB N/A
- AVG Volume (30 Days)
- LIDR 194.5K
- PMCB 17.8K
- Earning Date
- LIDR 05-08-2025
- PMCB 03-17-2025
- Dividend Yield
- LIDR N/A
- PMCB N/A
- EPS Growth
- LIDR N/A
- PMCB N/A
- EPS
- LIDR N/A
- PMCB 1.29
- Revenue
- LIDR $202,000.00
- PMCB N/A
- Revenue This Year
- LIDR $2,677.23
- PMCB N/A
- Revenue Next Year
- LIDR $409.09
- PMCB N/A
- P/E Ratio
- LIDR N/A
- PMCB $0.92
- Revenue Growth
- LIDR N/A
- PMCB N/A
- 52 Week Low
- LIDR $0.49
- PMCB $1.03
- 52 Week High
- LIDR $5.15
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- LIDR 59.40
- PMCB 43.09
- Support Level
- LIDR $0.61
- PMCB $1.11
- Resistance Level
- LIDR $0.68
- PMCB $1.27
- Average True Range (ATR)
- LIDR 0.05
- PMCB 0.11
- MACD
- LIDR 0.02
- PMCB 0.01
- Stochastic Oscillator
- LIDR 79.80
- PMCB 61.02
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.